Trial Outcomes & Findings for A Study of Sunitinib in Combination With Bevacizumab, Carboplatin, and Paclitaxel in Patients With Advanced Non-Small Cell Lung Cancer (SABRE-L) (NCT NCT00434226)

Last Updated: 2009-08-21

Results Overview

The best overall response is the best response, per RECIST criteria, recorded from randomization until disease progression/recurrence (includes both confirmed and unconfirmed responses). Although the original primary outcome was progression-free survival, there was insufficient data available to report on that outcome.

Recruitment status

TERMINATED

Study phase

PHASE2

Target enrollment

56 participants

Primary outcome timeframe

From randomization until disease progression/recurrence

Results posted on

2009-08-21

Participant Flow

Participant milestones

Participant milestones
Measure	Bevacizumab + Carboplatin/Paclitaxel + Sunitinib Bevacizumab intravenously at a dose of 15mg/kg on the first day of each 21-day cycle, carboplatin/paclitaxel on the first day of each cycle for 4 cycles, and sunitinib 25 mg/day for 2 weeks, followed by 1 week of rest	Bevacizumab + Carboplatin/Paclitaxel Bevacizumab intravenously at a dose of 15mg/kg on the first day of each 21-day cycle and carboplatin/paclitaxel on the first day of each cycle for 4 cycles
Overall Study STARTED	30	26
Overall Study COMPLETED	0	0
Overall Study NOT COMPLETED	30	26

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

A Study of Sunitinib in Combination With Bevacizumab, Carboplatin, and Paclitaxel in Patients With Advanced Non-Small Cell Lung Cancer (SABRE-L)

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure	Bevacizumab + Carboplatin/Paclitaxel + Sunitinib n=30 Participants Bevacizumab intravenously at a dose of 15mg/kg on the first day of each 21-day cycle, carboplatin/paclitaxel on the first day of each cycle for 4 cycles, and sunitinib 25 mg/day for 2 weeks, followed by 1 week of rest	Bevacizumab + Carboplatin/Paclitaxel n=26 Participants Bevacizumab intravenously at a dose of 15mg/kg on the first day of each 21-day cycle and carboplatin/paclitaxel on the first day of each cycle for 4 cycles	Total n=56 Participants Total of all reporting groups
Age Continuous	63.7 years STANDARD_DEVIATION 9.5 • n=5 Participants	64.8 years STANDARD_DEVIATION 10.7 • n=7 Participants	64.2 years STANDARD_DEVIATION 10.0 • n=5 Participants
Age, Customized <18 Years	0 participants n=5 Participants	0 participants n=7 Participants	0 participants n=5 Participants
Age, Customized Between 18 and 64 Years	15 participants n=5 Participants	13 participants n=7 Participants	28 participants n=5 Participants
Age, Customized >=65 Years	15 participants n=5 Participants	13 participants n=7 Participants	28 participants n=5 Participants
Sex: Female, Male Female	14 Participants n=5 Participants	12 Participants n=7 Participants	26 Participants n=5 Participants
Sex: Female, Male Male	16 Participants n=5 Participants	14 Participants n=7 Participants	30 Participants n=5 Participants

PRIMARY outcome

Timeframe: From randomization until disease progression/recurrence

Population: Randomized patients with at least one scan available at baseline and post-baseline

Outcome measures

Outcome measures
Measure	Bevacizumab + Carboplatin/Paclitaxel + Sunitinib n=25 Participants Bevacizumab intravenously at a dose of 15mg/kg on the first day of each 21-day cycle, carboplatin/paclitaxel on the first day of each cycle for 4 cycles, and sunitinib 25 mg/day for 2 weeks, followed by 1 week of rest	Bevacizumab + Carboplatin/Paclitaxel n=19 Participants Bevacizumab intravenously at a dose of 15mg/kg on the first day of each 21-day cycle and carboplatin/paclitaxel on the first day of each cycle for 4 cycles
Best Response Complete Response	0 participants	0 participants
Best Response Partial Response	12 participants	9 participants
Best Response Stable Disease	10 participants	9 participants
Best Response Progressive Disease	2 participants	1 participants
Best Response Unable to Evaluate	0 participants	0 participants
Best Response Missing	1 participants	0 participants

SECONDARY outcome

Timeframe: 60 days following the last administration of study treatment

Population: Treated patients

All grades according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), v3.0

Outcome measures

Outcome measures
Measure	Bevacizumab + Carboplatin/Paclitaxel + Sunitinib n=29 Participants Bevacizumab intravenously at a dose of 15mg/kg on the first day of each 21-day cycle, carboplatin/paclitaxel on the first day of each cycle for 4 cycles, and sunitinib 25 mg/day for 2 weeks, followed by 1 week of rest	Bevacizumab + Carboplatin/Paclitaxel n=26 Participants Bevacizumab intravenously at a dose of 15mg/kg on the first day of each 21-day cycle and carboplatin/paclitaxel on the first day of each cycle for 4 cycles
Serious Adverse Events Anaemia	0 participants	1 participants
Serious Adverse Events Febrile Neutropenia	4 participants	1 participants
Serious Adverse Events Neutropenia	1 participants	0 participants
Serious Adverse Events Thrombocytopenia	1 participants	0 participants
Serious Adverse Events Cardiac Arrest	1 participants	1 participants
Serious Adverse Events Diarrhoea	1 participants	0 participants
Serious Adverse Events Asthenia	0 participants	1 participants
Serious Adverse Events Disease Progression	1 participants	1 participants
Serious Adverse Events Fatigue	1 participants	0 participants
Serious Adverse Events Pain	0 participants	1 participants
Serious Adverse Events Hepatic Pain	0 participants	1 participants
Serious Adverse Events Drug Hypersensitivity	0 participants	1 participants
Serious Adverse Events Cellulitis	1 participants	0 participants
Serious Adverse Events Bacterial Sepsis	0 participants	1 participants
Serious Adverse Events Collapse of Lung	1 participants	0 participants
Serious Adverse Events Platelet Count Decreased	1 participants	0 participants
Serious Adverse Events Haemoglobin Decreased	0 participants	1 participants
Serious Adverse Events Nutrophil Count Decreased	0 participants	1 participants
Serious Adverse Events Dehydration	2 participants	1 participants
Serious Adverse Events Back Pain	1 participants	0 participants
Serious Adverse Events Lung Cancer Metastatic	0 participants	2 participants
Serious Adverse Events Gastric Cancer	1 participants	0 participants
Serious Adverse Events Non-Small Cell Lung Cancer	1 participants	0 participants
Serious Adverse Events Confusional State	0 participants	1 participants
Serious Adverse Events Renal Failure	0 participants	1 participants
Serious Adverse Events Pleural Effusion	0 participants	2 participants
Serious Adverse Events Pneumothorax	1 participants	0 participants
Serious Adverse Events Chronic Obstructive Pulmonary Disease	0 participants	2 participants
Serious Adverse Events Pulmonary Embolism	2 participants	0 participants
Serious Adverse Events Dyspnoea	0 participants	1 participants
Serious Adverse Events Haemoptysis	0 participants	1 participants
Serious Adverse Events Pneumonitis	1 participants	0 participants
Serious Adverse Events Pulmonary Haemorrhage	0 participants	1 participants
Serious Adverse Events Nasal Septum Perforation	1 participants	0 participants
Serious Adverse Events Aortic Aneurysm	1 participants	0 participants
Serious Adverse Events Hypotension	0 participants	1 participants

SECONDARY outcome

Timeframe: 60 days following the last administration of study treatment

Population: Treated patients

All grades according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), v3.0

Outcome measures

Outcome measures
Measure	Bevacizumab + Carboplatin/Paclitaxel + Sunitinib n=29 Participants Bevacizumab intravenously at a dose of 15mg/kg on the first day of each 21-day cycle, carboplatin/paclitaxel on the first day of each cycle for 4 cycles, and sunitinib 25 mg/day for 2 weeks, followed by 1 week of rest	Bevacizumab + Carboplatin/Paclitaxel n=26 Participants Bevacizumab intravenously at a dose of 15mg/kg on the first day of each 21-day cycle and carboplatin/paclitaxel on the first day of each cycle for 4 cycles
Incidence of Grade ≥ 3 Adverse Events Anaemia	1 participants	0 participants
Incidence of Grade ≥ 3 Adverse Events Febrile Nutropenia	4 participants	2 participants
Incidence of Grade ≥ 3 Adverse Events Leukopenia	6 participants	3 participants
Incidence of Grade ≥ 3 Adverse Events Neutropenia	18 participants	12 participants
Incidence of Grade ≥ 3 Adverse Events Thrombocytopenia	7 participants	5 participants
Incidence of Grade ≥ 3 Adverse Events Cardiac Arrest	1 participants	1 participants
Incidence of Grade ≥ 3 Adverse Events Left Ventricular Dysfunction	1 participants	0 participants
Incidence of Grade ≥ 3 Adverse Events Diarrhoea	1 participants	1 participants
Incidence of Grade ≥ 3 Adverse Events Gastrointestinal Haemorrhage	1 participants	0 participants
Incidence of Grade ≥ 3 Adverse Events Asthenia	0 participants	1 participants
Incidence of Grade ≥ 3 Adverse Events Disease Progression	1 participants	1 participants
Incidence of Grade ≥ 3 Adverse Events Fatigue	2 participants	3 participants
Incidence of Grade ≥ 3 Adverse Events Pain	1 participants	2 participants
Incidence of Grade ≥ 3 Adverse Events Hepatic Pain	0 participants	1 participants
Incidence of Grade ≥ 3 Adverse Events Drug Hypersensitivity	0 participants	1 participants
Incidence of Grade ≥ 3 Adverse Events Hypersensitivity	0 participants	1 participants
Incidence of Grade ≥ 3 Adverse Events Bacterial Sepsis	0 participants	1 participants
Incidence of Grade ≥ 3 Adverse Events Cellulitis	1 participants	0 participants
Incidence of Grade ≥ 3 Adverse Events Infection	1 participants	0 participants
Incidence of Grade ≥ 3 Adverse Events Pneumonia	0 participants	2 participants
Incidence of Grade ≥ 3 Adverse Events Collapse of Lung	1 participants	0 participants
Incidence of Grade ≥ 3 Adverse Events Aspartate Aminotransferase Increased	1 participants	0 participants
Incidence of Grade ≥ 3 Adverse Events Blood Alkaline Phosphatase Increased	1 participants	0 participants
Incidence of Grade ≥ 3 Adverse Events Fibrin D Dimer Increased	1 participants	0 participants
Incidence of Grade ≥ 3 Adverse Events Haemoglobin Decreased	0 participants	1 participants
Incidence of Grade ≥ 3 Adverse Events International Normalised Ratio Increased	1 participants	1 participants
Incidence of Grade ≥ 3 Adverse Events Nutrophil Count Decreased	1 participants	1 participants
Incidence of Grade ≥ 3 Adverse Events Platelet Count Decreased	4 participants	0 participants
Incidence of Grade ≥ 3 Adverse Events White Blood Cell Count Decreased	2 participants	0 participants
Incidence of Grade ≥ 3 Adverse Events Anorexia	1 participants	0 participants
Incidence of Grade ≥ 3 Adverse Events Dehydration	2 participants	1 participants
Incidence of Grade ≥ 3 Adverse Events Hyperglycaemia	0 participants	2 participants
Incidence of Grade ≥ 3 Adverse Events Hypoalbuminaemia	1 participants	0 participants
Incidence of Grade ≥ 3 Adverse Events Hypocalcaemia	0 participants	1 participants
Incidence of Grade ≥ 3 Adverse Events Hyponatraemia	0 participants	2 participants
Incidence of Grade ≥ 3 Adverse Events Arthralgia	0 participants	1 participants
Incidence of Grade ≥ 3 Adverse Events Back Pain	1 participants	0 participants
Incidence of Grade ≥ 3 Adverse Events Muscular Weakness	1 participants	0 participants
Incidence of Grade ≥ 3 Adverse Events Musculoskeletal Pain	1 participants	0 participants
Incidence of Grade ≥ 3 Adverse Events Gastric Cancer	1 participants	0 participants
Incidence of Grade ≥ 3 Adverse Events Lung Cancer Metastatic	0 participants	2 participants
Incidence of Grade ≥ 3 Adverse Events Metastases to Central Nervous System	1 participants	0 participants
Incidence of Grade ≥ 3 Adverse Events Non-Small Cell Lung Cancer	1 participants	0 participants
Incidence of Grade ≥ 3 Adverse Events Dizziness	1 participants	0 participants
Incidence of Grade ≥ 3 Adverse Events Confusional State	0 participants	1 participants
Incidence of Grade ≥ 3 Adverse Events Albuminuria	1 participants	0 participants
Incidence of Grade ≥ 3 Adverse Events Renal Failure	0 participants	1 participants
Incidence of Grade ≥ 3 Adverse Events Chronic Obstructive Pulmonary Disease	0 participants	1 participants
Incidence of Grade ≥ 3 Adverse Events Dyspnoea	2 participants	2 participants
Incidence of Grade ≥ 3 Adverse Events Pleural Effusion	0 participants	2 participants
Incidence of Grade ≥ 3 Adverse Events Pneumonitis	1 participants	0 participants
Incidence of Grade ≥ 3 Adverse Events Pulmonary Embolism	2 participants	1 participants
Incidence of Grade ≥ 3 Adverse Events Pulmonary Haemorrhage	0 participants	1 participants
Incidence of Grade ≥ 3 Adverse Events Leukocytoclastic Vasculitis	1 participants	0 participants
Incidence of Grade ≥ 3 Adverse Events Rash	2 participants	0 participants
Incidence of Grade ≥ 3 Adverse Events Aortic Aneurysm	1 participants	0 participants
Incidence of Grade ≥ 3 Adverse Events Hypertension	3 participants	1 participants

SECONDARY outcome

Timeframe: 60 days following the last administration of study treatment

Population: Treated patients

All grades according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), v3.0

Outcome measures

Outcome measures
Measure	Bevacizumab + Carboplatin/Paclitaxel + Sunitinib n=29 Participants Bevacizumab intravenously at a dose of 15mg/kg on the first day of each 21-day cycle, carboplatin/paclitaxel on the first day of each cycle for 4 cycles, and sunitinib 25 mg/day for 2 weeks, followed by 1 week of rest	Bevacizumab + Carboplatin/Paclitaxel Bevacizumab intravenously at a dose of 15mg/kg on the first day of each 21-day cycle and carboplatin/paclitaxel on the first day of each cycle for 4 cycles
Incidence of Adverse Events Leading to Sunitinib Discontinuation, Dose Interruption, or Dose Reduction Anaemia	1 participants	—
Incidence of Adverse Events Leading to Sunitinib Discontinuation, Dose Interruption, or Dose Reduction Febrile Nutropenia	2 participants	—
Incidence of Adverse Events Leading to Sunitinib Discontinuation, Dose Interruption, or Dose Reduction Leukopenia	4 participants	—
Incidence of Adverse Events Leading to Sunitinib Discontinuation, Dose Interruption, or Dose Reduction Neutropenia	11 participants	—
Incidence of Adverse Events Leading to Sunitinib Discontinuation, Dose Interruption, or Dose Reduction Thrombocytopenia	6 participants	—
Incidence of Adverse Events Leading to Sunitinib Discontinuation, Dose Interruption, or Dose Reduction Left Ventricular Dysfunction	1 participants	—
Incidence of Adverse Events Leading to Sunitinib Discontinuation, Dose Interruption, or Dose Reduction Diarrhoea	1 participants	—
Incidence of Adverse Events Leading to Sunitinib Discontinuation, Dose Interruption, or Dose Reduction Gastrointestinal Haemorrhage	1 participants	—
Incidence of Adverse Events Leading to Sunitinib Discontinuation, Dose Interruption, or Dose Reduction Nausea	1 participants	—
Incidence of Adverse Events Leading to Sunitinib Discontinuation, Dose Interruption, or Dose Reduction Stomatitis	1 participants	—
Incidence of Adverse Events Leading to Sunitinib Discontinuation, Dose Interruption, or Dose Reduction Disease Progression	1 participants	—
Incidence of Adverse Events Leading to Sunitinib Discontinuation, Dose Interruption, or Dose Reduction Fatigue	2 participants	—
Incidence of Adverse Events Leading to Sunitinib Discontinuation, Dose Interruption, or Dose Reduction Bronchitis	1 participants	—
Incidence of Adverse Events Leading to Sunitinib Discontinuation, Dose Interruption, or Dose Reduction Cellulitis	1 participants	—
Incidence of Adverse Events Leading to Sunitinib Discontinuation, Dose Interruption, or Dose Reduction Infection	1 participants	—
Incidence of Adverse Events Leading to Sunitinib Discontinuation, Dose Interruption, or Dose Reduction Collapse of Lung	1 participants	—
Incidence of Adverse Events Leading to Sunitinib Discontinuation, Dose Interruption, or Dose Reduction Aspartate Aminotransferase Increased	1 participants	—
Incidence of Adverse Events Leading to Sunitinib Discontinuation, Dose Interruption, or Dose Reduction Fibrin D Dimer Increased	1 participants	—
Incidence of Adverse Events Leading to Sunitinib Discontinuation, Dose Interruption, or Dose Reduction International Normalised Ratio Increased	1 participants	—
Incidence of Adverse Events Leading to Sunitinib Discontinuation, Dose Interruption, or Dose Reduction Neutrophil Count Decreased	1 participants	—
Incidence of Adverse Events Leading to Sunitinib Discontinuation, Dose Interruption, or Dose Reduction Platelet Count Decreased	5 participants	—
Incidence of Adverse Events Leading to Sunitinib Discontinuation, Dose Interruption, or Dose Reduction White Blood Cell Count Decreased	1 participants	—
Incidence of Adverse Events Leading to Sunitinib Discontinuation, Dose Interruption, or Dose Reduction Anorexia	1 participants	—
Incidence of Adverse Events Leading to Sunitinib Discontinuation, Dose Interruption, or Dose Reduction Dehydration	2 participants	—
Incidence of Adverse Events Leading to Sunitinib Discontinuation, Dose Interruption, or Dose Reduction Hypoalbuminaemia	1 participants	—
Incidence of Adverse Events Leading to Sunitinib Discontinuation, Dose Interruption, or Dose Reduction Back Pain	1 participants	—
Incidence of Adverse Events Leading to Sunitinib Discontinuation, Dose Interruption, or Dose Reduction Muscular Weakness	1 participants	—
Incidence of Adverse Events Leading to Sunitinib Discontinuation, Dose Interruption, or Dose Reduction Musculoskeletal Pain	1 participants	—
Incidence of Adverse Events Leading to Sunitinib Discontinuation, Dose Interruption, or Dose Reduction Gastric Cancer	1 participants	—
Incidence of Adverse Events Leading to Sunitinib Discontinuation, Dose Interruption, or Dose Reduction Metastases to Central Nervous System	1 participants	—
Incidence of Adverse Events Leading to Sunitinib Discontinuation, Dose Interruption, or Dose Reduction Non-Small Cell Lung Cancer	1 participants	—
Incidence of Adverse Events Leading to Sunitinib Discontinuation, Dose Interruption, or Dose Reduction Dizziness	1 participants	—
Incidence of Adverse Events Leading to Sunitinib Discontinuation, Dose Interruption, or Dose Reduction Albuminuria	1 participants	—
Incidence of Adverse Events Leading to Sunitinib Discontinuation, Dose Interruption, or Dose Reduction Pnemothorax	1 participants	—
Incidence of Adverse Events Leading to Sunitinib Discontinuation, Dose Interruption, or Dose Reduction Dyspnoea	2 participants	—
Incidence of Adverse Events Leading to Sunitinib Discontinuation, Dose Interruption, or Dose Reduction Pulmonary Embolism	2 participants	—
Incidence of Adverse Events Leading to Sunitinib Discontinuation, Dose Interruption, or Dose Reduction Leukocytoclastic Vasculitis	1 participants	—
Incidence of Adverse Events Leading to Sunitinib Discontinuation, Dose Interruption, or Dose Reduction Rash	1 participants	—
Incidence of Adverse Events Leading to Sunitinib Discontinuation, Dose Interruption, or Dose Reduction Aortic Aneurysm	1 participants	—
Incidence of Adverse Events Leading to Sunitinib Discontinuation, Dose Interruption, or Dose Reduction Hypertension	3 participants	—

SECONDARY outcome

Timeframe: 60 days following the last administration of study treatment

Population: Treated patients

All grades according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), v3.0

Outcome measures

Outcome measures
Measure	Bevacizumab + Carboplatin/Paclitaxel + Sunitinib n=29 Participants Bevacizumab intravenously at a dose of 15mg/kg on the first day of each 21-day cycle, carboplatin/paclitaxel on the first day of each cycle for 4 cycles, and sunitinib 25 mg/day for 2 weeks, followed by 1 week of rest	Bevacizumab + Carboplatin/Paclitaxel n=26 Participants Bevacizumab intravenously at a dose of 15mg/kg on the first day of each 21-day cycle and carboplatin/paclitaxel on the first day of each cycle for 4 cycles
Incidence of Adverse Events Leading to Bevacizumab Discontinuation or Dose Interruption Anaemia	1 participants	0 participants
Incidence of Adverse Events Leading to Bevacizumab Discontinuation or Dose Interruption Febrile Nutropenia	1 participants	1 participants
Incidence of Adverse Events Leading to Bevacizumab Discontinuation or Dose Interruption Leukopenia	1 participants	1 participants
Incidence of Adverse Events Leading to Bevacizumab Discontinuation or Dose Interruption Neutropenia	3 participants	1 participants
Incidence of Adverse Events Leading to Bevacizumab Discontinuation or Dose Interruption Thrombocytopenia	3 participants	2 participants
Incidence of Adverse Events Leading to Bevacizumab Discontinuation or Dose Interruption Cardiac Arrest	0 participants	1 participants
Incidence of Adverse Events Leading to Bevacizumab Discontinuation or Dose Interruption Diarrhoea	1 participants	0 participants
Incidence of Adverse Events Leading to Bevacizumab Discontinuation or Dose Interruption Gastrointestinal Haemorrhage	1 participants	0 participants
Incidence of Adverse Events Leading to Bevacizumab Discontinuation or Dose Interruption Disease Progression	1 participants	2 participants
Incidence of Adverse Events Leading to Bevacizumab Discontinuation or Dose Interruption Fatigue	2 participants	1 participants
Incidence of Adverse Events Leading to Bevacizumab Discontinuation or Dose Interruption Drug Hypersensitivity	0 participants	1 participants
Incidence of Adverse Events Leading to Bevacizumab Discontinuation or Dose Interruption Hypersensitivity	0 participants	1 participants
Incidence of Adverse Events Leading to Bevacizumab Discontinuation or Dose Interruption Bronchitis	1 participants	0 participants
Incidence of Adverse Events Leading to Bevacizumab Discontinuation or Dose Interruption Infection	1 participants	0 participants
Incidence of Adverse Events Leading to Bevacizumab Discontinuation or Dose Interruption Collapse of Lung	1 participants	0 participants
Incidence of Adverse Events Leading to Bevacizumab Discontinuation or Dose Interruption Aspartate Aminotransferase Increased	1 participants	0 participants
Incidence of Adverse Events Leading to Bevacizumab Discontinuation or Dose Interruption International Normalised Ratio Increased	1 participants	0 participants
Incidence of Adverse Events Leading to Bevacizumab Discontinuation or Dose Interruption Neutrophil Count Decreased	0 participants	1 participants
Incidence of Adverse Events Leading to Bevacizumab Discontinuation or Dose Interruption Platelet Count Decreased	5 participants	0 participants
Incidence of Adverse Events Leading to Bevacizumab Discontinuation or Dose Interruption Dehydration	2 participants	0 participants
Incidence of Adverse Events Leading to Bevacizumab Discontinuation or Dose Interruption Back Pain	1 participants	0 participants
Incidence of Adverse Events Leading to Bevacizumab Discontinuation or Dose Interruption Gastric Cancer	1 participants	0 participants
Incidence of Adverse Events Leading to Bevacizumab Discontinuation or Dose Interruption Lung Cancer Metastatic	0 participants	1 participants
Incidence of Adverse Events Leading to Bevacizumab Discontinuation or Dose Interruption Metastases to Central Nervous System	1 participants	0 participants
Incidence of Adverse Events Leading to Bevacizumab Discontinuation or Dose Interruption Metastases to Liver	0 participants	1 participants
Incidence of Adverse Events Leading to Bevacizumab Discontinuation or Dose Interruption Non-Small Cell Lung Cancer	1 participants	0 participants
Incidence of Adverse Events Leading to Bevacizumab Discontinuation or Dose Interruption Albuminuria	1 participants	0 participants
Incidence of Adverse Events Leading to Bevacizumab Discontinuation or Dose Interruption Renal Failure	0 participants	1 participants
Incidence of Adverse Events Leading to Bevacizumab Discontinuation or Dose Interruption Haemoptysis	0 participants	1 participants
Incidence of Adverse Events Leading to Bevacizumab Discontinuation or Dose Interruption Pleural Effusion	0 participants	1 participants
Incidence of Adverse Events Leading to Bevacizumab Discontinuation or Dose Interruption Pneumothorax	1 participants	0 participants
Incidence of Adverse Events Leading to Bevacizumab Discontinuation or Dose Interruption Pulmonary Embolism	2 participants	0 participants
Incidence of Adverse Events Leading to Bevacizumab Discontinuation or Dose Interruption Rash	1 participants	0 participants
Incidence of Adverse Events Leading to Bevacizumab Discontinuation or Dose Interruption Aortic Aneurysm	1 participants	0 participants
Incidence of Adverse Events Leading to Bevacizumab Discontinuation or Dose Interruption Hypertension	2 participants	2 participants
Incidence of Adverse Events Leading to Bevacizumab Discontinuation or Dose Interruption Hypotension	0 participants	1 participants

Adverse Events

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Medical Communications Specialist

Genentech, Inc.

Phone: 800-821-8590

Results disclosure agreements

Principal investigator is a sponsor employee The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study.
Publication restrictions are in place

Restriction type: OTHER